Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by SVB Wealth LLC

SVB Wealth LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,569 shares of the medical instruments supplier’s stock after buying an additional 171 shares during the period. SVB Wealth LLC’s holdings in Becton, Dickinson and Company were worth $1,602,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Fairfield Bush & CO. acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth $114,000. Sequoia Financial Advisors LLC boosted its stake in Becton, Dickinson and Company by 11.3% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock worth $778,000 after purchasing an additional 297 shares during the period. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 8.8% during the 1st quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $368,000 after purchasing an additional 112 shares during the period. Zions Bancorporation N.A. boosted its stake in Becton, Dickinson and Company by 13.0% during the 1st quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock worth $134,000 after purchasing an additional 58 shares during the period. Finally, Mather Group LLC. boosted its stake in Becton, Dickinson and Company by 26.0% during the 1st quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock worth $358,000 after purchasing an additional 278 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.4 %

BDX stock opened at $233.15 on Friday. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32. The stock has a market capitalization of $67.36 billion, a PE ratio of 55.25, a price-to-earnings-growth ratio of 1.91 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The company has a fifty day moving average of $240.19 and a 200-day moving average of $242.58.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.98 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were issued a $0.95 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. Barclays increased their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James raised their target price on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.